Literature DB >> 22586172

Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey.

Benjamin Terrier1, Fabrice Carrat, Evguenia Krastinova, Isabelle Marie, David Launay, Adeline Lacraz, Pauline Belenotti, Luc de Saint Martin, Thomas Quemeneur, Antoine Huart, Fabrice Bonnet, Guillaume Le Guenno, Jean-Emmanuel Kahn, Olivier Hinschberger, Patricia Rullier, Aurelie Hummel, Elisabeth Diot, Christian Pagnoux, Estibaliz Lzaro, Frank Bridoux, Thierry Zenone, Olivier Hermine, Jean-Marc Leger, Xavier Mariette, Patricia Senet, Emmanuelle Plaisier, Patrice Cacoub.   

Abstract

BACKGROUND: Data on the prognosis of non-infectious mixed cryoglobulinaemia vasculitis (CryoVas) in the era of hepatitis C virus screening are lacking.
METHODS: The French multicentre and retrospective CryoVas survey included 242 patients with non-infectious mixed CryoVas. Causes of death and prognostic factors of survival were assessed and a prognostic score was determined to predict survival at 5 years.
RESULTS: After a median follow-up of 35 months, 42 patients (17%) died. Causes of death were mainly serious infections (50%) and vasculitis flare (19%). One-, 2-, 5- and 10-year overall survival rates were 91%, 89%, 79% and 65%, respectively. A prognostic score, the CryoVas score (CVS), for the prediction of survival at 5 years was devised. Pulmonary and gastrointestinal involvement, glomerular filtration rate <60 ml/min and age >65 years were independently associated with death. At 5 years the death rates were 2.6%, 13.1%, 29.6% and 38.5% for a CVS of 0, 1, 2 and ≥3, respectively. At 1 year the death rates were 0%, 3.2%, 18.5% and 30.8% for a CVS of 0, 1, 2 and ≥3, respectively. The CVS was strongly correlated with the Five Factor Score (FFS) 2009, another prognostic score validated in primary necrotising vasculitis (r=0.82; p<0.0001). The area under the curve for the CVS was 0.74 compared with 0.67 for the FFS, indicating a better performance of the CVS (p=0.052).
CONCLUSIONS: In patients with non-infectious mixed CryoVas, the main prognostic factors are age >65 years, pulmonary and gastrointestinal involvement and renal failure. A score including these variables is significantly associated with the prognosis.

Entities:  

Mesh:

Year:  2012        PMID: 22586172     DOI: 10.1136/annrheumdis-2012-201405

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

1.  Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN.

Authors:  Mohamad Zaidan; Benjamin Terrier; Agnieszka Pozdzik; Thierry Frouget; Nathalie Rioux-Leclercq; Christian Combe; Sébastien Lepreux; Aurélie Hummel; Laure-Hélène Noël; Isabelle Marie; Bruno Legallicier; Arnaud François; Antoine Huart; David Launay; Gilles Kaplanski; Frank Bridoux; Philippe Vanhille; Raifah Makdassi; Jean-François Augusto; Philippe Rouvier; Alexandre Karras; Chantal Jouanneau; Marie-Christine Verpont; Patrice Callard; Fabrice Carrat; Olivier Hermine; Jean-Marc Léger; Xavier Mariette; Patricia Senet; David Saadoun; Pierre Ronco; Isabelle Brochériou; Patrice Cacoub; Emmanuelle Plaisier
Journal:  J Am Soc Nephrol       Date:  2015-08-10       Impact factor: 10.121

Review 2.  The complexity of an overlap type resistant cryoglobulinemia: a case report and review of the literature.

Authors:  Milena Tocut; Ziv Rozman; Alexander Biro; Asher Winder; Amir Tanay; Gisele Zandman-Goddard
Journal:  Clin Rheumatol       Date:  2019-01-10       Impact factor: 2.980

Review 3.  HCV-negative mixed cryoglobulinemia and kidney involvement: in-depth review on physiopathological and histological bases.

Authors:  Leonardo Spatola; Elena Generali; Claudio Angelini; Salvatore Badalamenti; Carlo Selmi
Journal:  Clin Exp Med       Date:  2018-06-28       Impact factor: 3.984

Review 4.  Gastrointestinal aspects of vasculitides.

Authors:  Medha Soowamber; Adam V Weizman; Christian Pagnoux
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-23       Impact factor: 46.802

5.  Effectiveness of cryofiltration and mizoribine combination with oral steroid therapy in a patient with membranoproliferative glomerulonephritis due to essential cryoglobulinemia.

Authors:  Yuka Kurokawa; Kiyomi Koike; Yusuke Kaida; Sakuya Ito; Hirotane Chiba; Kengo Urae; Tomofumi Moriyama; Nao Nakamura; Tetsurou Imai; Ryo Shibata; Takuma Hazama; Daisuke Wakasugi; Seiya Okuda; Kei Fukami
Journal:  CEN Case Rep       Date:  2019-03-29

Review 6.  Non-infectious cryoglobulinemia vasculitis (CryoVas): update on clinical and therapeutic approach.

Authors:  Rodolfo Perez-Alamino; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2014-05       Impact factor: 4.592

7.  Clinical Spectrum and Renal Outcome of Cryoglobulinemia in Hong Kong.

Authors:  Winston Wing-Shing Fung; Terry Cheuk-Fung Yip; Vincent Wai-Sun Wong; Kai-Ming Chow; Grace Lai-Hung Wong; Cheuk-Chun Szeto
Journal:  Kidney360       Date:  2021-02-22

Review 8.  Diagnostics and treatment of cryoglobulinaemia: it takes two to tango.

Authors:  Jan Damoiseaux; Jan Willem Cohen Tervaert
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 9.  [Cryoglobulinemic vasculitis].

Authors:  N Blank; H-M Lorenz
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

10.  [Recommendations on the use of rituximab for ANCA-associated vasculitis].

Authors:  A M Gause; A Rubbert-Roth
Journal:  Z Rheumatol       Date:  2014-04       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.